So here's how you get a biotech stock to move on a Monday morning: announce a partnership that could be worth over $2 billion. Shares of Telix Pharmaceuticals (TLX) were up about 5.8% to $11.15 in premarket trading after the company said it's teaming up with Regeneron (REGN) to develop next-generation radiopharmaceutical cancer therapies.
Think of it as a classic biotech handshake deal with some serious numbers attached. Telix, an Australian radiopharmaceutical company, brings its development platform and global manufacturing capabilities to the table. Regeneron, the U.S. biotech giant, brings its deep expertise in biologics and antibody discovery—specifically antibodies generated from its proprietary VelocImmune mice. Together, they're going after multiple solid tumor targets from Regeneron's antibody portfolio.
The financial terms are what make this interesting for Telix shareholders. The company gets $40 million upfront for four initial programs. Then there's optionality: Telix can choose to co-fund commercialization and share profits, or it can earn milestone payments instead. Those milestones could add up to an aggregate $2.1 billion across development and commercial goals, plus low double-digit royalties on any products that make it to market. That's the kind of deal that gets investors' attention before the market even opens.
This isn't Telix's only news lately. On Thursday, the FDA accepted the company's resubmitted New Drug Application for TLX101-Px1 (also known as Pixclara 2), an investigational PET imaging agent for glioma, a type of brain cancer. The agency set a PDUFA goal date of September 11, which means we'll know by then whether it gets approved. For a company in the precision oncology space, having both therapeutic development partnerships and diagnostic imaging progress is a good look.
The company's financials are holding up too. Telix reported first-quarter interim sales of $230 million, up 11% sequentially. Its Precision Medicine revenue specifically came in at $186 million, a 16% increase from the previous quarter. More importantly, management reaffirmed its fiscal 2026 revenue outlook of $950 million to $970 million. They also maintained R&D spending guidance of $200 million to $240 million, which they say is tied to advancing global commercial and clinical milestones.
Speaking of clinical milestones: back in March, Telix announced that Part 1 of its global Phase 3 ProstACT study met its primary endpoints. The study evaluated TLX591-Tx for prostate cancer and showed an acceptable safety and tolerability profile, supporting its therapeutic potential. When you're trying to convince a big partner like Regeneron to work with you, having positive Phase 3 data in your back pocket certainly doesn't hurt.
So what we have here is a radiopharmaceutical company that's executing on multiple fronts: solid financials, pipeline progress, regulatory movement, and now a potentially transformative partnership with one of the industry's heavyweights. The market seems to like the story so far—up nearly 6% before the opening bell tells you that much. Whether that $2.1 billion in potential milestones ever materializes is a question for the future, but for now, Telix has given investors plenty to talk about over their Monday morning coffee.
